Many options for expressing proteins in mammalian cells
Versatile Mammalian Expression Vectors:A Review
Quinn Lu • Tanya Hosfield • Mary Buchanan • Kerstein
Padgett Stratagene
We describe Stratagene’s pcmv-script®, pCMV-Tag1 through 5, and
pdual® expression vectors* and present data to
illustrate their features. These vectors offer convenient options, such as
high-fidelity PCR cloning, epitope tagging, or dual expression in
prokaryotic and eukaryotic systems. All three vector systems are designed
specifically for high-level expression of gene products in mammalian
cells. By evaluating the unique features of each expression vector, it is
simple to select the one best suited for a specific experimental
system.
The demand for versatile mammalian expression vectors is growing, since
many researchers study eukaryotic gene transcription and translation. In
many instances, achieving posttranslational modifications of a gene
product of interest is necessary to obtain an active eukaryotic protein.
Vectors with convenient options, such as the capacity for high-fidelity
PCR cloning and epitope tagging for characterization studies, have become
integral to sophisticated research inquiries.
Stratagene offers versatile mammalian expression vectors that provide a
variety of options for functional studies of gene products. These options
include the following: potential for gene expression in both bacterial and
mammalian cells; availability of antibiotic selection for both bacterial
and/or mammalian cells; inclusion of regulatory sequences for high
expression levels; ability to clone PCR fragments generated from a variety
of PCR enzymes; possibility for classical cloning method,
seamless® cloning method* or PCR-Script™ cloning
method; and presence of epitope and affinity tags in variable positions
for in vivo studies of gene products. Hence, it is easy to choose an
expression vector (Table 1) that best
fits the research parameters.
Table 1
Mammalian Expression Vectors
| |
pcmv-script®
vector |
pdual®
vector |
pCMV-Tag1
vector |
pCMV-Tag2
vector |
pCMV-Tag3
vector |
pCMV-Tag4
vector |
pCMV-Tag5
vector |
Mammalian
Expression |
Yes |
Yes |
Yes |
Yes |
Yes |
Yes |
Yes |
Bacterial
Expression |
No |
Yes |
No |
No |
No |
No |
No |
Promoter |
CMV |
CMV (mutated) |
CMV |
CMV |
CMV |
CMV |
CMV |
PolyA |
SV40 (early) |
SV40 (late) |
SV40 (early) |
SV40 (early) |
SV40 (early) |
SV40 (early) |
SV40 (early) |
Cloning
Strategy |
PCR-Script™
cloning or MCS |
seamless®
cloning |
Multiple cloning site (MCS) |
MCS in all
3 reading frames |
MCS in all
3 reading frames |
MCS in all
3 reading frames |
MCS in all
3 reading frames |
Selection |
Kanamycin (bacterial) or
G418 (mammalian) |
Kanamycin
(bacterial) or
G418 (mammalian) |
Kanamycin
(bacterial) or
G418 (mammalian) |
Kanamycin
(bacterial) or
G418 (mammalian) |
Kanamycin
(bacterial) or
G418 (mammalian) |
Kanamycin
(bacterial) or
G418 (mammalian) |
Kanamycin
(bacterial) or
G418 (mammalian) |
Purification
Tag |
No |
Calmodulin
binding peptide (CBP) affinity tag |
FLAG® and/or
c-myc epitopes |
FLAG epitope |
c-myc epitope |
FLAG epitope |
c-myc epitope |
Tag Position |
N/A |
C-terminus |
FLAG
(N- or C- terminal or internal), and/or
c-myc (C-terminal) |
N-terminal |
N-terminal |
C-terminal |
C-terminal |
Translation
Initiation Sequences |
Provided by insert |
Shine-Delgarno and Kozak |
Kozak or provided by insert |
Kozak |
Kozak |
Provided by insert |
Provided by insert
|
Efficient Cloning of PCR Fragments
Stratagene’s pcmv-script® PCR cloning kit is an expression system that
is a mammalian adaptation of the PCR-Script cloning strategy.1
This method for cloning PCR-generated fragments is popular because it is
efficient, easy to use, and superior to other available
methods.2 In the PCR-Script cloning method, PCR products are
incubated with the predigested PCR-Script vector, Srf I restriction
enzyme, and T4 DNA ligase. The Srf I enzyme recognizes the rare
oligonucleotide sequence 5¢-GCCCGGGC-3¢ in the vector and recircularizes any vector
that ligates to itself without an insert. Once an insert has ligated to
the vector, the site is destroyed.
By including the Srf I enzyme in the ligation reaction, the
PCR-Script cloning method maintains high concentrations of digested vector
DNA and allows the use of nonphosphorylated, unmodified PCR products. This
method ensures a low background of recircularized vector and increased
ligation efficiency for blunt-ended DNA fragments by the simultaneous,
opposing reactivity of the Srf I enzyme and T4 DNA ligase on
nonrecombinant vector DNA.

Figure 1
The PCR-Script method is used in the pCMV-Script PCR cloning kit, which
features the pCMV-Script vector (Figure 1), a
mammalian expression vector that uses the CMV promoter ### for
constitutive expression in a wide variety of cell lines. The pCMV-Script
vector shares many of the essential characteristics of the PCR-Script
vector: the multiple cloning site (MCS), capacity to clone inserts
generated with any PCR enzyme, high efficiency, and 1-hour ligation.
However, the pCMV-Script vector also has many distinctive features. It
contains the neomycin-phosphotransferase gene under dual control of the
b-lactamase and SV40 promoters, which
selects for kanamycin resistance in bacteria and G418 resistance in
mammalian cells. Classical cloning strategies are also possible with the
pCMV-Script vector’s MCS; Xho I and EcoR I sites are
included to construct directional cDNA libraries.3
Expression in the pCMV-Script Vector
In order to demonstrate the cloning efficiency of the pCMV-Script PCR
cloning kit, a number of PCR products were cloned into the pCMV-Script
vector.1 One of these constructs, the firefly luciferase gene,
was used to transfect Chinese hamster ovary (CHO) cells. To compare the
expression level of this reporter gene inserted into the pCMV-Script
vector with the expression level in another available vector product, we
also inserted the luciferase gene into the pcDNA 3.1 vector (Invitrogen,
San Diego, CA). Each construct and appropriate controls were used to
transfect CHO cells. Forty-eight hours following transfection, CHO cells
were harvested, luciferase activity was quantitated (Figure 2), and the
protein of the correct molecular weight was detected by Western blot
analysis (data not shown). Luciferase activity and expression from the
pCMV-Script vector were equivalent to that of the pcDNA 3.1 vector.

Figure 2
Use Tag-Specific Antibodies to Study Gene Products
Stratagene offers another option to clone and express mammalian genes
by applying the useful epitope- tagging technique: A protein of interest
is fused to a peptide-epitope that is recognized by a commercially
available antibody. Epitope tagging can be used to localize gene products
in living cells, identify associated proteins, track movement of
fusion proteins within the cell, characterize new proteins or
immunoprecipitate fusion proteins. Epitope tagging makes functional
studies of a target protein possible while eliminating the cost, labor,
and time required to generate a specific antibody to that protein.

Figure 3
Stratagene’s pCMV-Tag1 through 5 vectors (Figure 3) are a
series of epitope-tagging vectors designed for gene expression in
mammalian cells that contain either the FLAG® coding
sequence§§ and/or c-myc epitope-coding sequences. Because the
FLAG and c-myc epitopes are small, they usually do not interfere with the
function of the target protein. They are also highly immunoreactive,
allowing detection with commercially available antibodies. The FLAG
epitope is a synthetic peptide that consists of eight amino acid residues
(DYKDDDDK).4 The c-myc epitope is derived from the human c-myc
gene and contains 10 amino acid residues (EQKLISEEDL).5
For the pCMV-Tag1 vector, a variety of tagging positions are possible.
A target gene inserted into the pCMV-Tag1 vector can be tagged with the
FLAG epitope (N-terminal, C-terminal, or internal tagging), the c-myc
epitope (C-terminal), or both the FLAG (N-terminal) and c-myc (C-terminal)
epitopes.6 The pCMV-Tag2 vector contains sequences for
N-terminal tagging with the FLAG epitope, and the pCMV-Tag3 vector is used
for N-terminal tagging with the c-myc epitope. For constructing C-terminal
fusion proteins, the pCMV-Tag4 vector includes the sequence for the FLAG
epitope, and the pCMV-Tag5 vector features the sequence for the c-myc
epitope. Each of the pCMV-Tag2 through 5 vectors offers specific tagging
positions and is available as a kit that includes vectors in all three
reading frames to simplify subcloning. All constructs generated in the
pCMV-Tag vectors can be transfected into mammalian cells, and fusion
proteins can be easily characterized using commercially available,
tag-specific antibodies.
The pCMV-Tag1 through 5 vectors feature not only optimized propagation
and expression of fusion proteins in eukaryotic cells, but also attributes
conferred by their pCMV-Script vector backbone. Thus, the pCMV-Tag1
through 5 vectors include constitutive expression of the cloned DNA in a
wide variety of mammalian cell lines and the capability of selecting
stable transformants by kanamycin resistance in bacteria and G418
resistance in mammalian cells. The Kozak consensus sequence of CC(A or
G)CCATGG provides optimal expression of the fusion protein for N-terminal
epitope tags.
Expression and Detection of Epitope Tags

Figure 4
To demonstrate how easy it is to detect epitope tags, we performed
Western blot analyses of cell lysates derived from CHO cells transfected
with the pCMV-Tag2 through 5 vectors containing the luciferase gene insert
(Figure 4).
Aliquots of these lysates were fractionated on three separate protein gels
and transferred to nitrocellulose. The membranes were probed individually
with anti-luciferase, anti-FLAG, or anti-c-myc antibodies. Results
indicate that the fusion protein, with either FLAG or c-myc at N-terminal
or C-terminal positions, is easily detected by Western blot analysis (Figure 4).
To demonstrate that luciferase tagged terminally with either FLAG or
c-myc is biologically active, we cloned the luciferase gene into the
pCMV-Tag2 through 5 vectors to create constructs with all possible tagging
options: N-terminal tagging with FLAG, N-terminal tagging with c-myc,
C-terminal tagging with FLAG and C-terminal tagging with c-myc. Assays of
cell lysates made from transient transfections of these constructs into
CHO cells and COS cells showed significant luciferase activity, whereas
lysates from control transfections showed only background levels of
luciferase activity (data not shown).
Dual Expression in Bacterial and Mammalian Cells

Figure 5
Stratagene also offers the unique pDual vector (Figure 5), which
features high-level expression of heterologous genes in both mammalian and
bacterial systems. The regulatory features of vectors for mammalian and
bacterial expression vary considerably; each type of vector offers
different choices of promoters, splice signals, and polyadenylation sites,
as well as their respective translation initiation sequences. Oftentimes,
a eukaryotic gene must first be cloned into a bacterial vector, then the
gene must be subcloned into a vector suitable for eukaryotic expression.
However, Stratagene’s pDual expression vector8 eliminates the
need to subclone from one vector system into another.
The pDual vector features constitutive expression of cloned DNA in a
wide variety of mammalian cell lines and the capability of selecting
stable transformants by G418 resistance in mammalian cells. For bacterial
systems, the pDual vector contains the hybrid T7/lacO
promoter‡‡, which provides inducible protein expression with
IPTG. The T7 RNA polymerase promoter provides the highest levels of
protein expression in E. coli. The presence of the lac repressor
gene (lacI) on the plasmid confers tight repression of the system.
The pDual vector has tandemly arranged bacterial
Shine-Dalgarno9 and mammalian Kozak7 consensus
sequences. These tandem consensus sequences ensure optimal translation
initiation in both bacterial and mammalian systems, because each ribosome
binding site is positioned at its optimal distance from the initiation
codon of the cloned target gene. When using the pDual vector, researchers
may option to express the protein in its native form or fuse their target
gene to the 4-kDa calmodulin-binding peptide (CBP) affinity tag. This CBP
tag allows the fusion protein to be easily detected with Stratagene’s
Affinity™ CBP fusion detection kit and purified with Calmodulin
Affinity Resin.8
Seamless Cloning
The pDual expression vector can be used in conjunction with the
Seamless cloning kit.10 For the Seamless cloning technique, the
target gene is PCR-amplified using primers that contain the Eam1104
I restriction sites and a minimal flanking sequence, which permits rapid
and efficient cloning in the presence of the type IIS Eam1104 I
restriction enzyme. After digesting the PCR product with Eam1104 I,
the fragment can be inserted via a three nucleotide 5¢ overhang that encodes the target gene’s own ATG. The type
IIS Eam1104 I restriction enzyme eliminates any primer-related
residual nucleotides that are generally present when regular restriction
enzyme recognition sites are specified by the PCR primer sequences.
Conclusions
Together, the pCMV-Script, pCMV-Tag1 through 5, and pDual vectors offer
a variety of options to express gene products in mammalian cells. Choose
among these versatile vectors to optimize gene cloning for mammalian
expression in any experimental system. For the pCMV-Script vector, there
is high-level constitutive expression from the CMV promoter, cloning using
either classical or PCR-Script cloning technology, and stable transfection
via the neomycin-resistance gene. For the pCMV-Tag1 through 5 vectors,
target genes can be inserted for tagging with FLAG and/or c-myc epitopes.
When these constructs are transfected into mammalian cells, functional
studies of the tagged-fusion proteins are possible using commercially
available tag-specific antibodies. The pDual vector provides expression in
both bacterial and mammalian systems and features a hybrid bacterial
promoter for inducible bacterial expression. This vector can be used in
conjunction with the Seamless cloning technique.
REFERENCES
-
Hosfield, T., et al. (1997) Strategies 10: 68-69.
-
Bauer, J., et al. (1992) Strategies 5: 62-65.
-
Lu, Q., et al. (1997) Strategies 10: 119-120.
-
Hopp, H.P., et al. (1988) Biotechnology 6:
1204-1210.
-
Evan, G.I., et al. (1985) Mol. Cell Biol. 5:
3610-3616.
-
Hosfield, T. and Lu, Q. (1998) BioTechniques (in
press).
-
Kozak, M. (1991) J. Biol. Chem. 266: 19867-19870.
-
Padgett, K.A. and Sorge, J.A. (1997) Strategies
10: 97-99.
-
Shine, J. and Dalgarno, L. (1974) Proc. Natl. Acad.
Sci. USA 71: 1342-1346.
-
Padgett, K.A. and Sorge, J.A. (1996) Gene 168:
31-35.
* Patent pending. |